The current financial score of ANI Pharmaceuticals Inc is 9.09. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 266.04M, representing a year-over-year increase of 25.87%, while its net profit experienced a year-over-year increase of 214.08%.
The current valuation score of ANI Pharmaceuticals Inc is 8.66. Its current P/E ratio is 17.89, which is 559.85% below the recent high of 118.04 and 907.61% above the recent low of -144.47.
The current earnings forecast score of ANI Pharmaceuticals Inc is 8.50. The average price target is 107.43, with a high of 121.00 and a low of 90.00.
The current price momentum score of ANI Pharmaceuticals Inc is 3.30. Currently, the stock price is trading between the resistance level at 78.49 and the support level at 69.14, making it suitable for range-bound swing trading.
The current institutional shareholding score of ANI Pharmaceuticals Inc is 10.00. The latest institutional shareholding proportion is 101.74%, representing a quarter-over-quarter increase of 1.25%. The largest institutional shareholder is John Hussman, holding a total of 31.50K shares, representing 0.60% of shares outstanding, with 1.00% increase in holdings.
The current risk assessment score of ANI Pharmaceuticals Inc is 8.50. The company's beta value is 0.45. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.